Plasma Glucosylsphingosine in GBA1 E365K , N409S, and L483P Heterozygous Mutation Carriers
Movement Disorders · 2026
DOI: 10.1002/mds.70205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, 2026. Verfasst von Julian Agin-Liebes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Columbia University Irving Medical Center, New York, USA. Hauptthemen laut MEDLINE: Glucosylceramidase, Psychosine, Parkinson Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Parkinson's Foundation, Michael J. Fox Foundation for Parkinson's Research, NIH HHS.
Abstract (Originalsprache)
Background
GBA1 encodes the lysosomal enzyme glucocerebrosidase, with key substrates that include glucosylceramide and glucosylsphingosine. The E365K variant is the most common variant in GBA1 that is associated with Parkinson's disease (PD) but is not associated with Gaucher disease. Plasma glucosylsphingosine levels have previously been shown to be higher in GBA1 N409S heterozygous carriers, but its levels in E365K carriers are unknown.
Objective
The aim was to measure plasma glucosylsphingosine levels in GBA1 N409S, E365K, and L483P heterozygous mutation carriers with and without PD.
Methods
Glucosylsphingosine was quantified in plasma from 112 participants using liquid chromatography–tandem mass spectrometry targeted quantification.
Results
Plasma glucosylsphingosine concentration was significantly higher in N409S (0.59 ng/mL, p = 0.004), E365K (0.59 ng/mL, p = 0.01), and L483P (0.63 ng/mL, p = 0.003) heterozygotes compared to noncarriers (0.45 ng/mL), independent of disease status.
Conclusions
Elevated plasma glucosylsphingosine confirms reduced glucocerebrosidase function in E365K carriers. © 2026 Merck &Co. Inc. and The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Columbia University Irving Medical Center, New York, USA.
- Merck & Co., Inc, Rahway, New Jersey, USA.
- The Michael J. Fox Foundation for Parkinson's Research, New York, USA.
- Department of Neurology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
- Tel Aviv Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
ORCID-Profile: Alexander Haimovich
Förderung
- Parkinson's Foundation
- Michael J. Fox Foundation for Parkinson's Research
- NIH HHS
- National Institutes of Health
Zitieren
APA
Agin-Liebes, J., Haimovich, A., Griep, R., Hatcher, N. G., Yao, L., Waters, C., Padmanabhan, S., & Alcalay, R. N. (2026). Plasma Glucosylsphingosine in GBA1 E365K , N409S, and L483P Heterozygous Mutation Carriers. Movement Disorders. https://doi.org/10.1002/mds.70205
Vancouver
Agin-Liebes J, Haimovich A, Griep R, Hatcher NG, Yao L, Waters C, et al. Plasma Glucosylsphingosine in GBA1 E365K , N409S, and L483P Heterozygous Mutation Carriers. Movement Disorders. 2026. doi:10.1002/mds.70205
BibTeX
@article{AginLiebes2026,
author = {Agin-Liebes, Julian and Haimovich, Alexander and Griep, Rachel and Hatcher, Nathan Galen and Yao, Lihang and Waters, Cheryl and Padmanabhan, Shalini and Alcalay, Roy N},
title = {Plasma Glucosylsphingosine in GBA1 E365K , N409S, and L483P Heterozygous Mutation Carriers},
journal = {Movement Disorders},
year = {2026},
doi = {10.1002/mds.70205}
}
EUVIMED